24,902 results match your criteria Myelodysplastic Syndrome


The non-erythroid myeloblast count rule in myelodysplastic syndromes: fruitful or futile?

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, The Netherlands;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.212563DOI Listing

Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes. A diagnostic accuracy study.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Centre Hospitalier Universitaire de Clermont-Ferrand, France.

Suspicion of myelodysplastic syndromes is one of the commonest reasons for bone marrow aspirate in elderly patients presenting with persistent peripheral blood cytopenia of unclear etiology. A peripheral blood assay that accurately rules out myelodysplastic syndromes would have major benefits. The diagnostic accuracy of the intraindividual robust coefficient of variation for neutrophil myeloperoxidase expression measured by flow cytometric analysis in peripheral blood was evaluated in a retrospective derivation study (44 myelodysplastic syndrome cases and 44 controls) and a prospective validation study (68 consecutive patients with suspected myelodysplastic syndromes). Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.202275DOI Listing
April 2019
1 Read

Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Department of Internal Medicine, Section of Hematology, Yale School of Medicine;

Immunosuppressive therapy is one therapy option for treatment of patients with lower-risk myelodysplastic syndromes. However, the use of several different immunosuppressive regimens, the lack of high-quality studies, and the absence of validated predictive biomarkers pose important challenges. We conducted a systematic review and meta-analysis according to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines and searched MEDLINE via PubMed, Ovid EMBASE, COCHRANE registry of clinical trials (CENTRAL), and the Web of Science without language restriction from inception through September 2018 as well as relevant conference proceedings and abstracts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.219345DOI Listing

Vitamin K-antagonism impairs the bone marrow microenvironment and hematopoiesis.

Blood 2019 Apr 19. Epub 2019 Apr 19.

Georg-Speyer-Haus, Germany

Vitamin K antagonists (VKA) have been used in 1% of the world's population for prophylaxis or treatment of thromboembolic events for 64 years. Impairment of osteoblast function and osteoporosis has been described in patients on VKA. Given the involvement of cells of the bone marrow microenvironment (BMM), such as mesenchymal stem cells (MSC) and macrophages, as well as other factors like the extracellular matrix for the maintenance of normal hematopoietic stem cells (HSC), we investigated a possible impact of VKA on hematopoiesis via the BMM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2018874214DOI Listing

Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group.

Mod Pathol 2019 Apr 18. Epub 2019 Apr 18.

Department of Pathology and Laboratory Medicine, University of Chicago, Chicago, IL, USA.

Acute undifferentiated leukemia is a rare type of acute leukemia that shows no evidence of differentiation along any lineage. Clinical, immunophenotypic and genetic data is limited and it is uncertain if acute undifferentiated leukemia is biologically distinct from acute myeloid leukemia with minimal differentiation, which also shows limited myeloid marker expression and has been reported to have a poor prognosis. We identified 92 cases initially diagnosed as acute undifferentiated leukemia or acute myeloid leukemia with minimal differentiation from pathology databases of nine academic institutions with available diagnostic flow cytometric data, cytogenetic findings, mutational and clinical data. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41379-019-0263-3
Publisher Site
http://dx.doi.org/10.1038/s41379-019-0263-3DOI Listing
April 2019
1 Read

[Effects of Low-Dose Decitabine on Soluble CD44, GDF11 Levels and Hematopoietic Function in Elderly Patients with MDS].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):509-514

Department of Hematology, Hengshui Harrison International Peace Hospital, Hengshui 053000, Hebei Province, China,E-mail:

Objective: To investigate the effects of low-dose decitabine on levels of soluble CD44 and GDF11, and hematopoietic function in elderly patients with myelodysplastic syndrome (MDS).

Methods: Ninety-nine patients with senile myelodysplastic syndrome (MDS) admitted to our hospital from October 2015 to October 2017 were divided into group A, B and C according to their treatment, each with 33 cases.The patients in group A were treated with low-dose decitabine, the patients in group B were treated with usual dose of decitabine, and the patients in group C were treated with low-dose decitabine plus G-GSF, cytarabine, and aclarithromycin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.032DOI Listing
April 2019
1 Read

[Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):494-503

Fujian Institute of Hematology,Fujian Provincial Key Laboratory on Hematology,Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.

Objective: To systematically evaluate the efficacy and safety of DCAG regimen for treating the intermediate or high risk MDS and AML.

Methods: PubMed, EMbase, The Cochrane Library, WanFang Data and CNKI databases were searched to collect randomized controlled trials (RCTs) of decitabine combined with CAG regimen for intermediate or high risk MDS and AML from inception to March, 2018. The quality of each RCT was evaluated by the Cochrane collaboration´s tool for assessing the risk of bias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.030DOI Listing
April 2019
2 Reads

A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation.

Leuk Lymphoma 2019 Apr 18:1-10. Epub 2019 Apr 18.

u University Hospital Eppendorf , Hamburg , Germany.

Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). Transfusions may cause iron-related toxicity and mortality, influencing outcome after allogeneic HSCT. This prospective non-interventional study evaluated 222 MDS and CMML patients undergoing HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1594215DOI Listing

R-ChIP for genome-wide mapping of R-loops by using catalytically inactive RNASEH1.

Nat Protoc 2019 Apr 17. Epub 2019 Apr 17.

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.

Nascent RNA may form a three-stranded structure with DNA, called an R-loop, which has been linked to fundamental biological processes such as transcription, replication and genome instability. Here, we provide a detailed protocol for a newly developed strategy, named R-ChIP, for robust capture of R-loops genome-wide. Distinct from R-loop-mapping methods based on the monoclonal antibody S9. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41596-019-0154-6
Publisher Site
http://dx.doi.org/10.1038/s41596-019-0154-6DOI Listing
April 2019
2 Reads

Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-Associated Inflammatory Bowel Disease.

Intern Med 2019 Apr 17. Epub 2019 Apr 17.

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan.

Autoimmune diseases including inflammatory bowel disease (IBD) occur in association with myelodysplastic syndrome (MDS). MDS-associated IBD frequently demonstrates a complicated course. We herein report the first case with MDS-associated IBD that was successfully treated with ustekinumab (UST), an anti-interleukin (IL) 12/23p40 monoclonal antibody. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2495-18DOI Listing
April 2019
1 Read

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.

Genes Chromosomes Cancer 2019 Apr 17. Epub 2019 Apr 17.

Clinics of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.

The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of the new comprehensive cytogenetic scoring system for MDS, chromosome 7 anomalies are no longer generally assigned to poor risk features but are thoroughly separated. However, der(1;7)(q10;p10), hereinafter der(1;7), is merged into the group labelled "any other single" and belongs to the intermediate risk group, just by definition due to lack of adequate clinical data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22760DOI Listing

Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine.

Cancer Med 2019 Apr 16. Epub 2019 Apr 16.

Université Paris-Saclay, Université Paris-Sud, CESP (Center for Research in Epidemiology and Population Health), Inserm, Team Cancer and Environment, Villejuif, France.

We performed a retrospective analysis of 93 myelodysplastic syndromes (MDS) patients with intermediate 2 or high-risk IPSS score to study the impact of Azacitidine (AZA) relative dose intensity (RDI) <80% on the overall survival (OS). There were 51.6% of patients who had full dose and 48. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2121DOI Listing
April 2019
1 Read

Cladribine-related myelodysplastic syndrome in Langerhans cell histiocytosis.

Pediatr Int 2019 Apr 17. Epub 2019 Apr 17.

Department of Pediatrics, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ped.13792DOI Listing

Heterogeneity of Mesenchymal Stromal Cells in Myelodysplastic Syndrome-with Multilineage Dysplasia (MDS-MLD).

Indian J Hematol Blood Transfus 2019 Apr 1;35(2):223-232. Epub 2019 Jan 1.

Centre for Stem Cell Research, A Unit of inStem Bengaluru, Christian Medical College Campus, Bagayam, Vellore, Tamil Nadu 632002 India.

Bone marrow niche constituents have been implicated in the genesis of clonal hematopoietic dysfunction in myelodysplastic syndromes (MDS), though the exact role of stroma in the pathogenesis of MDS remains to be defined. We have evaluated the characteristics of mesenchymal stromal cells in a cohort of patients with MDS with multilineage dysplasia (MDS-MLD). MSCs were cultured from bone marrow aspirates of MDS-MLD patients and controls with healthy bone marrow. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-018-1062-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439082PMC
April 2019
1 Read

3D Telomere Structure Analysis to DetectGenomic Instability and Cytogenetic Evolutionin Myelodysplastic Syndromes.

Cells 2019 Apr 2;8(4). Epub 2019 Apr 2.

Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, The Genomic Centre for Cancer Research and Diagnosis, R3E 0V9 Winnipeg, MB, Canada.

The disease course of myelodysplastic syndromes (MDS) features chromosome instability and clonal evolution, leading to the sequential acquisition of novel cytogenetic aberrations and the accumulation of these abnormalities in the bone marrow. Although clonal cytogenetic abnormalities can be detected by conventional cytogenetics in 50% of patients with MDS, such distinguishing patterns are lacking in the other 50%. Despite the increase in the prognostic value of some biomarkers, none of them is specific and able to discriminate between stable and unstable patients that subsequently progress to acute myeloid leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells8040304DOI Listing
April 2019
1 Read

An Integrated Regulatory Network Based on Comprehensive Analysis of mRNA Expression, Gene Methylation and Expression of Long Non-coding RNAs (lncRNAs) in Myelodysplastic Syndromes.

Front Oncol 2019 29;9:200. Epub 2019 Mar 29.

Department of Haematology, Huashan Hospital, Fudan University, Shanghai, China.

Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by ineffective hematopoiesis, defective differentiation of hematopoietic precursors, and expansion of the abnormal clones. The prevalence of MDS has raised great concerns worldwide, but its pathogenetic mechanisms remain elusive. To provide insights on novel biomarkers for the diagnosis and therapy of MDS, we performed high-throughput genome-wide mRNA expression profiling, DNA methylation analysis, and long non-coding RNAs (lncRNA) analysis on bone marrows from four MDS patients and four age-matched healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450213PMC
March 2019
1 Read

Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.

Ann Hematol 2019 Apr 12. Epub 2019 Apr 12.

Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, 34 Zhongshan North Road, Quanzhou, 362000, Fujian Province, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03674-2DOI Listing
April 2019
1 Read

Getting personal with myelodysplastic syndromes: is now the right time?

Expert Rev Hematol 2019 Apr 12:1-10. Epub 2019 Apr 12.

a Section of Hematology, Department of Internal Medicine , Yale University School of Medicine , New Haven , CT , USA.

Introduction: Commonly used scoring systems rely on blood counts, histological and cytological examination of bone marrow and peripheral blood as well as cytogenetic assessments to estimate prognosis of patients with myelodysplastic syndromes (MDS) and guide therapy decisions. Next-generation sequencing (NGS) has identified recurrent genetic abnormalities in up to 90% of patients with MDS and may provide important information regarding the pathogenesis of the disease, diagnostic and prognostic evaluation, and therapy selection. Areas covered: Herein, the authors review the role of NGS in diagnosis, treatment, and prognosis of MDS at various disease stages, and discuss advantages and caveats of incorporating molecular genetics in routine management of MDS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1592673DOI Listing
April 2019
2 Reads

Anthropometric factors and risk of myeloid leukaemias and myelodysplastic syndromes: a prospective study and meta-analysis.

Br J Haematol 2019 Apr 11. Epub 2019 Apr 11.

Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.

There is insufficient evidence linking excess body weight to risk of myeloid malignancies. We investigated this association using data from the Cancer Prevention Study-II (CPS-II), and a meta-analysis of published cohort studies. Among 152 090 CPS-II participants, 387 acute myeloid leukaemias (AML), 100 chronic myeloid leukaemias (CML) and 170 MDS were identified over 21 years of follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15904DOI Listing
April 2019
1 Read

The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome.

Front Oncol 2019 27;9:192. Epub 2019 Mar 27.

Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.

Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445951PMC
March 2019
1 Read

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.

Blood Adv 2019 Apr;3(8):1197-1210

Western University, London, ON, Canada.

Purpose: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.

Methods: PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ESAs, the literature search was expanded to include meta-analyses and RCTs in patients with cancer or chronic kidney disease and cohort studies in patients with cancer due to limited RCT evidence in the cancer setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018030387DOI Listing
April 2019
2 Reads

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.

J Clin Oncol 2019 Apr 10:JCO1802142. Epub 2019 Apr 10.

13 Western University, London, Ontario, Canada.

Purpose: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.

Methods: PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ESAs, the literature search was expanded to include meta-analyses and RCTs in patients with cancer or chronic kidney disease and cohort studies in patients with cancer due to limited RCT evidence in the cancer setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.02142DOI Listing
April 2019
1 Read

Serum Vitamin D Levels in Patients with Myelodysplastic Syndromes: A Retrospective Single-Center Analysis.

Acta Haematol 2019 Apr 9;141(4):225-231. Epub 2019 Apr 9.

Department of Medicine III, Hematology and Oncology, Technische Universität München, Munich, Germany.

Background/aims: There is growing evidence supporting the role of innate immune deregulation and inflammation in the pathogenesis of myelodysplastic syndromes (MDS). Vitamin D (VD) is known to be involved in various immune and epigenetic processes. This analysis aimed to evaluate serum VD levels in patients with MDS and to analyze associations between serum VD levels and disease characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496014DOI Listing
April 2019
1 Read

Suboptimal Response Rates to Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia; a Single Institutional Study of 121 Patients.

Am J Hematol 2019 Apr 9. Epub 2019 Apr 9.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Hypomethylating agents (HMA) are currently the only FDA approved therapy for patients with chronic myelomonocytic leukemia (CMML). In the current retrospective study, we assessed response rates as adjudicated by the IWG (International Working Group) MDS (myelodysplastic syndrome) and MDS/myeloproliferative neoplasm (MPN) overlap syndrome response criteria, in 121 CMML patients treated with Azacitidine (AZA, n=56) and Decitabine (DAC, n=65). The overall response rates were 41% by the IWG MDS (AZA- 45%, DAC-39%) and 56% by the IWG MDS/MPN (AZA-56%, DAC-58%) response criteria, with CR (complete remission) rates of <20% for both agents, by both criteria; without significant differences in response rates between proliferative and dysplastic CMML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25488DOI Listing
April 2019
1 Read

The Fraction of CD117/c-KIT-Expressing Erythroid Precursors Predicts ESA Response in Low-Risk Myelodysplastic Syndromes.

Cytometry B Clin Cytom 2019 Apr 9. Epub 2019 Apr 9.

Service d'Hématologie-Immunologie-Transfusion, Hôpitaux Universitaires Paris Ile de France Ouest, Boulogne 92100, France.

Background: Compelling evidence has emerged for the relevance of flow cytometry (FC) in the diagnostic work-up of myelodysplastic syndromes (MDS) but due to technical issues, the erythroid lineage has been under investigated, specifically in the therapeutic context.

Methods: Using the "no red cell lysis" method developed to set up the RED-score, we specifically quantified the fraction of CD117/c-KIT-expressing erythroid precursors in a cohort of 144 MDS patients and studied the correlation with response to erythropoiesis-stimulating agents (ESA) in a sub cohort of 63 low-risk MDS patients.

Results: We confirmed the previously reported increase in CD117/c-KIT-expressing erythroid precursors in a subset of MDS patients and demonstrated a strong association between a cut off of CD117/c-KIT-expressing erythroid precursors ≥3% and ESA response (P = 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21781DOI Listing
April 2019
1 Read

Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes.

Leukemia 2019 Apr 8. Epub 2019 Apr 8.

Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA.

The transforming growth factor (TGF)-β superfamily comprises more than 30 soluble growth factors that play a central role in erythropoiesis and are part of a tightly regulated myelosuppressive negative feedback loop under physiologic conditions. TGF-β receptor activation and phosphorylation trigger a regulatory circuit of activating and inhibitory SMAD proteins and increased activation of the TGF-β signaling pathway either by a loss of negative feedback or constitutive activation has been associated with the myelosuppression and ineffective erythropoiesis in myelodysplastic syndromes (MDS). Anemia is the predominant cause of morbidity and quality of life impairment in patients with lower-risk (LR)-MDS, and there are very limited therapy options for these patients after failure of erythropoiesis stimulating agents (ESAs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0448-2DOI Listing
April 2019
1 Read

Health Care Utilization is High in Adult Patients Relapsing After Allogeneic Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

Division of Blood and Marrow Transplantation, Department of Medicine, Stanford, CA.

Disease relapse is the leading cause of death for patients with acute leukemia (AL) and myelodyspastic syndrome (MDS) who undergo allogeneic hematopoietic cell transplantation (HCT). Relapse post-HCT is associated with poor prognosis; however, the inpatient health care utilization of this population is unknown. Here we describe survival, intensity of health care utilization, and characteristics associated with high resource utilization at the end-of-life (EOL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.001DOI Listing
April 2019
1 Read

Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia.

Leuk Lymphoma 2019 Apr 8:1-3. Epub 2019 Apr 8.

f Sorbonne University, Internal Medicine Department, Saint Antoine Hospital , Paris , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1599114DOI Listing
April 2019
1 Read

Corrigendum to 'Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation' [Biology of Blood and Marrow Transplantation 21/11 (2015) 1939-1947].

Biol Blood Marrow Transplant 2019 Apr 4. Epub 2019 Apr 4.

Peking University People's Hospital & Peking University Institute of Hematology, Beijing, China; Peking-Tsinghua Center for Life Sciences, Beijing, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.007DOI Listing
April 2019
1 Read

Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome.

Clin Cancer Res 2019 Apr 5. Epub 2019 Apr 5.

Medicine, Duke University

Purpose: Myelodysplastic syndrome (MDS) is associated with a dysregulated innate immune system. The purpose of this study was to determine whether modulation of the innate immune system via high mobility group box-1 (HMGB1) could reduce cell viability in MDS.

Experimental Design: We quantified HMGB1 in a MDS cell line MDS-L and in primary MDS cells compared to non-malignant hematopoietic cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3517DOI Listing
April 2019
1 Read

Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation.

J Natl Cancer Inst 2019 Feb 14. Epub 2019 Feb 14.

Background: High intensity treatments such as hematopoietic cell transplantation (HCT) can be curative for patients with hematologic malignancies, but this needs to be balanced by the high risk of nonrelapse mortality (NRM) during the first 2 years after HCT. Sarcopenia (low muscle mass) is associated with physical disability and premature mortality in individuals with nonmalignant diseases and may be a predictor of NRM and poor overall survival in patients undergoing HCT.

Methods: This was a retrospective cohort study of 859 patients with acute leukemia or myelodysplastic syndrome who underwent a first HCT as adults (≥18 years) between 2007 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djy231DOI Listing
February 2019
2 Reads

Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study.

Haematologica 2019 Apr 4. Epub 2019 Apr 4.

Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston MA

Quality of response to immunosuppressive therapy and long-term outcomes for pediatric severe aplastic anemia remain incompletely characterized. Contemporary evidence to inform treatment of relapsed or refractory severe aplastic anemia are also limited for pediatric patients. The clinical features and outcomes for 314 children treated from 2002-2014 with immunosuppressive therapy for acquired severe aplastic anemia were analyzed retrospectively from 25 institutions in the North American Pediatric Aplastic Anemia Consortium. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.206540DOI Listing
April 2019
12 Reads

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

Clin Lymphoma Myeloma Leuk 2019 Mar 11. Epub 2019 Mar 11.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA. Electronic address:

Background: Patients with chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy are at increased risk of developing therapy-related (t-) myelodysplastic syndrome (MDS). It is unclear whether antecedent CLL adds prognostic value to the revised International Prognostic Scoring System (IPSS-R) for MDS. We performed a retrospective analysis to evaluate the significance of a previous CLL diagnosis as an independent adverse prognostic factor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.03.003DOI Listing
March 2019
2 Reads

Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine.

Leuk Lymphoma 2019 Apr 5:1-7. Epub 2019 Apr 5.

d Hematology Division, 2nd Department of Internal Medicine , "ATTIKO" General University Hospital, National and Kapodistrian University of Athens , Athens , Greece.

The aim of the present study was to identify biomarkers predictive of the outcome of patients with high-risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia (AML) treated with 5-azacytidine (AZA). We prospectively examined the association between NK-cytotoxic activity, myeloid-derived suppressor cells (MDSCs), and T-regulatory cells (Tregs) on the overall survival (OS) of patients. Patients with NK-cytotoxicity above a critical threshold had a longer duration of response and survived longer than patients with severe impairment of NK-cytotoxicity. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2019.1581935DOI Listing
April 2019
6 Reads

Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome.

Br J Haematol 2019 Apr 2. Epub 2019 Apr 2.

Department of Haematology, Kanazawa University Hospital, Kanazawa, Japan.

Though second allogenic haematopoietic stem cell transplantation (HSCT) is considered a curative treatment option after myelodysplastic syndrome (MDS) relapse, scant epidemiological data are available. We investigated the outcomes and prognostic factors of second allogenic HSCT in 99 patients with MDS who relapsed after the first HSCT. The median age was 53 years (interquartile; 45-59) and 57 patients (57·6%) were male. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15898DOI Listing
April 2019
2 Reads

Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome.

Leukemia 2019 Apr 2. Epub 2019 Apr 2.

Department of Haematological Medicine, King's College Hospital, London, UK.

Diagnostic criteria for hypoplastic myelodysplasic syndrome (h-MDS) have not been clearly established, making the differential diagnosis from other bone marrow failure syndromes (BMF) challenging. In this study, we aimed to delineate clinical, histopathological, and molecular features of h-MDS, based on a large and well-annotated cohort of patients with bone marrow (BM) hypocellularity. The study included 534 consecutive adult patients with hypocellular BM (278 h-MDS and 136 aplastic anemia), and 727 with normo- or hypercellular MDS (n-MDS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0457-1DOI Listing
April 2019
3 Reads

Insertional mutagenesis using the Sleeping Beauty transposon system identifies drivers of erythroleukemia in mice.

Sci Rep 2019 Apr 2;9(1):5488. Epub 2019 Apr 2.

Divisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.

Insertional mutagenesis is a powerful means of identifying cancer drivers in animal models. We used the Sleeping Beauty (SB) transposon/transposase system to identify activated oncogenes in hematologic cancers in wild-type mice and mice that express a stabilized cyclin E protein (termed cyclin ET74AT393A). Cyclin E governs cell division and is misregulated in human cancers. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-019-41805-x
Publisher Site
http://dx.doi.org/10.1038/s41598-019-41805-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445099PMC
April 2019
4 Reads

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.

Pharmaceutics 2019 Apr 1;11(4). Epub 2019 Apr 1.

Clinical Pharmacy, Saarland University, 66123 Saarbrücken, Germany.

The protein therapeutic and CD95L inhibitor asunercept is currently under clinical investigation for the treatment of glioblastoma and myelodysplastic syndrome. The purpose of this study was to predict the asunercept pharmacokinetics in children and to give dose recommendations for its first use in pediatric glioblastoma patients. A physiologically-based pharmacokinetic (PBPK) model of asunercept in healthy and diseased adults was successfully developed using the available clinical Phase I and Phase II study data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/pharmaceutics11040152DOI Listing

Clonal hematopoiesis and preleukemia-Genetics, biology, and clinical implications.

Genes Chromosomes Cancer 2019 Apr 2. Epub 2019 Apr 2.

Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany.

Myeloid neoplasms including myelodysplastic syndromes and acute myeloid leukemia (AML) originate from hematopoietic stem cells through sequential acquisition of genetic and epigenetic alterations that ultimately cause the disease-specific phenotype of impaired differentiation and increased proliferation. It has become clear that preleukemic clonal hematopoiesis (CH), characterized by an expansion of stem and progenitor cells that carry somatic mutations but are still capable of normal differentiation, can precede the development of clinically overt myeloid neoplasia by many years. CH commonly develops in the aging hematopoietic system, yet progression to myelodysplasia or AML is rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22756DOI Listing
April 2019
15 Reads

A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia.

Case Rep Hematol 2019 27;2019:8612031. Epub 2019 Feb 27.

Department of Hematology and Oncology, Kita-Harima Medical Center, Hyogo, Japan.

A 67-year-old male, with a known diagnosis of myelodysplastic syndromes with multilineage dysplasia (MDS-MLD) was admitted to our hospital with a primary complaint of subcutaneous bleeding in his left thigh. Laboratory data showed anaemia and prolongation of activated partial thromboplastin time (85.8 s, normal range 24-39 s) without thrombocytopenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8612031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415290PMC
February 2019
4 Reads

Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS.

Blood 2019 Apr 1. Epub 2019 Apr 1.

Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;

This study was performed to assess the utility of tumor-derived fragmentary DNA, or circulating tumor DNA (ctDNA), for identifying high-risk patients for relapse of acute myeloid leukemia and myelodysplastic syndrome (AML/MDS) after undergoing myeloablative allogeneic stem cell transplantation (alloSCT). We retrospectively collected tumor and available matched serum samples at diagnosis and 1 and 3 months post-alloSCT from 53 patients with AML/MDS. After identifying driver mutations in 51 patients using next-generation sequencing, we designed at least one personalized digital-PCR assay per case. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-880690DOI Listing
April 2019
4 Reads

Trilineage Dysplasia in an Adolescent With Germline GATA2 Mutation.

J Pediatr Hematol Oncol 2019 Mar 29. Epub 2019 Mar 29.

Department of Pathology and Laboratory Medicine, University of Vermont Medical Center.

The GATA family of DNA binding proteins consists of six different transcription factors (GATA1-6), each with diverse biologic function. The GATA2 protein has been shown to be vital for proliferation and maintenance of hematopoietic stem cells; mutations result in variable phenotypes including myelodysplastic syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001469DOI Listing
March 2019
4 Reads

Pernicious Anaemia with Normal Vitamin B12.

Eur J Case Rep Intern Med 2019 18;6(2):001045. Epub 2019 Feb 18.

Medicine Department, Hospital da Luz, Lisbon, Portugal.

A 49-year-old female patient presented to our hospital with asthenia, odynophagia, low grade fever, worsening symptoms of chronic depression, and symmetric leg paresthesias. Investigations showed macrocytic anaemia, leucopenia, thrombocytopenia, high lactate dehydrogenase levels and a normal Coombs test. Trilineage dysplasia was detected in the bone marrow biopsy specimen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2019_001045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432825PMC
February 2019
1 Read

[Myelodysplastic syndromes: recent advances in prognostic risk stratification systems].

Authors:
M Y Du H Mei Y Hu

Zhonghua Xue Ye Xue Za Zhi 2019 Mar;40(3):252-255

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.03.019DOI Listing
March 2019
2 Reads